Kalaris Therapeutics Inc
KLRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.13 | 0.16 | 0.01 | -0.03 |
| FCF Yield | -148.22% | -116.49% | -80.61% | -427.18% |
| EV / EBITDA | 1.24 | -0.64 | -0.81 | 0.86 |
| Quality | ||||
| ROIC | -48.77% | 2,210.84% | 781.58% | -66.90% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.15 | 0.96 | 0.63 | 0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -379.09% | -44.51% | 90.80% | -74.20% |
| Safety | ||||
| Net Debt / EBITDA | 2.01 | 0.23 | -0.01 | 1.01 |
| Interest Coverage | 0.00 | -19.60 | -59.60 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -2,732.11 |